CDT Equity Executes 1-for-25 Reverse Stock Split to Boost Share Price

Event summary

  • CDT Equity's board approved a 1-for-25 reverse stock split, effective March 26, 2026.
  • The split reduces outstanding shares from ~118 million to ~4.7 million.
  • Trading under the same ticker (CDT) begins March 27, 2026, with a new CUSIP number.
  • Shareholders receive proportional adjustments or cash for fractional shares.
  • The move follows prior shareholder approval for future reverse splits.

The big picture

CDT Equity's reverse split aligns with a broader trend of biotech firms optimizing capital structures amid volatile markets. The move follows its 2023 business combination, signaling a shift toward platform-driven innovation. With ~$50M in projected 2026 revenue, the company aims to leverage AI and solid-form chemistry to reposition therapeutic assets—though execution risks remain high in competitive R&D spaces.

What we're watching

Market Perception
How the split affects investor confidence and trading liquidity.
Nasdaq Compliance
Whether the reduced share count ensures continued listing.
Strategic Pivot
The pace at which CDT advances AI-driven drug development post-split.